Your browser doesn't support javascript.
loading
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.
Graham, Simon P; McLean, Rebecca K; Spencer, Alexandra J; Belij-Rammerstorfer, Sandra; Wright, Daniel; Ulaszewska, Marta; Edwards, Jane C; Hayes, Jack W P; Martini, Veronica; Thakur, Nazia; Conceicao, Carina; Dietrich, Isabelle; Shelton, Holly; Waters, Ryan; Ludi, Anna; Wilsden, Ginette; Browning, Clare; Bialy, Dagmara; Bhat, Sushant; Stevenson-Leggett, Phoebe; Hollinghurst, Philippa; Gilbride, Ciaran; Pulido, David; Moffat, Katy; Sharpe, Hannah; Allen, Elizabeth; Mioulet, Valerie; Chiu, Chris; Newman, Joseph; Asfor, Amin S; Burman, Alison; Crossley, Sylvia; Huo, Jiandong; Owens, Raymond J; Carroll, Miles; Hammond, John A; Tchilian, Elma; Bailey, Dalan; Charleston, Bryan; Gilbert, Sarah C; Tuthill, Tobias J; Lambe, Teresa.
Afiliación
  • Graham SP; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • McLean RK; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Spencer AJ; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Belij-Rammerstorfer S; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Wright D; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Ulaszewska M; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Edwards JC; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Hayes JWP; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Martini V; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Thakur N; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Conceicao C; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Dietrich I; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Shelton H; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Waters R; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Ludi A; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Wilsden G; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Browning C; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Bialy D; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Bhat S; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Stevenson-Leggett P; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Hollinghurst P; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Gilbride C; Department of Microbial Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7XH UK.
  • Pulido D; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Moffat K; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Sharpe H; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Allen E; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Mioulet V; The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ UK.
  • Chiu C; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Newman J; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Asfor AS; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Burman A; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Crossley S; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Huo J; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Owens RJ; Protein Production UK, Research Complex at Harwell, and Rosalind Franklin Institute Rutherford Appleton Laboratory Harwell Oxford, Didcot, OX11 0FA UK.
  • Carroll M; Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford, OX3 7BN UK.
  • Hammond JA; Protein Production UK, Research Complex at Harwell, and Rosalind Franklin Institute Rutherford Appleton Laboratory Harwell Oxford, Didcot, OX11 0FA UK.
  • Tchilian E; Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford, OX3 7BN UK.
  • Bailey D; Public Health England, Manor Farm Road, Salisbury, SP4 0JG UK.
  • Charleston B; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Gilbert SC; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Tuthill TJ; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
  • Lambe T; The Pirbright Institute, Ash Road, Pirbright, GU24 0NF UK.
NPJ Vaccines ; 5(1): 69, 2020.
Article en En | MEDLINE | ID: mdl-32793398
ABSTRACT
Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2020 Tipo del documento: Article